Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation
暂无分享,去创建一个
A. Knudson | W. Linehan | C. Ricketts | C. Vocke | K. Devarajan | A. Godwin | J. Testa | R. Uzzo | E. Henske | L. Kopelovich | A. Bellacosa | J. Crowell | E. Nicolas | E. Ross | R. Tricarico | M. Cheung | A. Yeung | M. Clapper | E. Caretti | K. Campbell | S. Peri | L. Vanderveer | S. Howard | C. Menges | P. Conrad | Eleonora Sementino | Elena Caretti | Sharon Howard | Craig W. Menges
[1] R. Nussbaum,et al. Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2014, The American journal of surgical pathology.
[2] D. Kwiatkowski,et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. , 2014, Human molecular genetics.
[3] E. Aronica,et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. , 2014, Cerebral cortex.
[4] A. Knudson,et al. Meta-Analysis Identifies NF-κB as a Therapeutic Target in Renal Cancer , 2013, PloS one.
[5] L. Kopelovich,et al. Heritable one-hit events defining cancer prevention? , 2013, Cell cycle.
[6] W. Kaelin,et al. The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.
[7] L. Cantley,et al. Breathless cancer cells get fat on glutamine , 2012, Cell Research.
[8] K. Rantanen,et al. Prolyl Hydroxylase PHD3 Enhances the Hypoxic Survival and G1 to S Transition of Carcinoma Cells , 2011, PloS one.
[9] Jiannis Ragoussis,et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.
[10] H. Friess,et al. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer , 2010, British Journal of Cancer.
[11] Peter H. Baenziger,et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers , 2010, Oncotarget.
[12] B. Brüne,et al. High glucose concentrations attenuate hypoxia-inducible factor-1alpha expression and signaling in non-tumor cells. , 2010, Experimental cell research.
[13] Karthik Devarajan,et al. Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations , 2010, Cancer Prevention Research.
[14] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[15] W. Rathmell,et al. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo , 2009, Oncogene.
[16] W. Kaelin. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.
[17] Bhavinkumar B. Patel,et al. One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. , 2008, Cancer research.
[18] Margit Rosner,et al. The mTOR pathway and its role in human genetic diseases. , 2008, Mutation research.
[19] K. Devarajan,et al. Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection , 2008, Journal of cellular biochemistry.
[20] B. Ebert,et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. , 2007, Molecular cell.
[21] Robert Gentleman,et al. Using GOstats to test gene lists for GO term association , 2007, Bioinform..
[22] N. Denko,et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.
[23] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[24] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[25] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] L. del Peso,et al. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. , 2005, The Biochemical journal.
[27] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[28] A. Knudson,et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations , 2004, Cancer biology & therapy.
[29] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[30] L. del Peso,et al. The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen* , 2003, Journal of Biological Chemistry.
[31] Alfonso Bellacosa,et al. Genetic hits and mutation rate in colorectal tumorigenesis: Versatility of Knudson's theory and implications for cancer prevention , 2003, Genes, chromosomes & cancer.
[32] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[33] A. Knudson,et al. National Cancer Institute Workshop Report: the phakomatoses revisited. , 2000, Journal of the National Cancer Institute.
[34] J. Licht,et al. WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts , 1999, Oncogene.
[35] E. Henske,et al. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. , 1998, Cancer research.
[36] R. Snell,et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. , 1998, Human molecular genetics.
[37] O. Yoshida,et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy , 1998, International journal of cancer.
[38] W. Risau,et al. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.
[39] B. Ponder,et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. , 1997, Human molecular genetics.
[40] M. Bertagnolli,et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.
[41] A. Webster,et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.
[42] W. Linehan,et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.
[43] A. Rustgi. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. , 1994, The New England journal of medicine.
[44] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[45] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[46] Yu Wang,et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. , 2007, Cancer research.
[47] W. Linehan,et al. Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.
[48] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .